COVID-19 REINFECTION BETWEEN DOSES OF VACCINATION: CASE REPORT IN A CITY OF BRAZIL’S SOUTHEAST
Resumen
Vaccination against COVID-19 is happening worldwide, with most vaccines requiring 2 doses to reach its maximum potential. It is the most efficient measure to prevent new cases of COVID-19, both of infection and reinfection. This case reports the reinfection of a female receptionist at an urgent care facility, where the research group was testing and monitoring symptoms of patients with flu syndrome, in the city of Belo Horizonte, Minas Gerais, Brasil, where she reinfected between the two preconized doses. Her initial infection occurred in September 2020 and reinfection in February 2021, 14 days after the first dose - both confirmed by RT-PCR - with reportedly worse symptoms on the latter. We warn for the possibility of reinfection episodes even after the first dose of vaccination, differently from what literature stated so far, so that health agents can organize more effective security measures, in a context of viral mutation and of new strains.Citas
BUSS, L. F.; PRETE-JUNIOR, C. A.; ABRAHIM, C. M. M. et al. Three-quarters attack rate of SARS-CoV-2 in the Brazilian Amazon during a largely unmitigated epidemic. Science, v. 371, n. 6526, p. 288-292, 2021.
COSTA, M. S.; SATO, H. I.; ROCHA, R. P. et al. Adjusting the Cut-Off and Maximum Pool Size in RT-qPCR Pool Testing for SARS-CoV-2. Viruses, v. 13, n. 4, p. 557, 2021.
FINTELMAN-RODRIGUES, N.; DA SILVA, A. P.D.; DOS SANTOS, M. C. et al. Genetic Evidence and Host Immune Response in Persons Reinfected with SARS-CoV-2, Brazil. Emerging Infectious Diseases, v. 27, n. 5, p. 1446-1453, 2021.
FREITAS, A. R. R.; BECKEDORFF, O. A.; CAVALCANTI, L. P. G.; SIQUEIRA, A. M.; CASTRO, D. B. de; COSTA, C. F. da et al. The Emergence of Novel SARS-CoV-2 Variant P.1 in Amazonas (Brazil) Was Temporally Associated with a Change in the age and Gender Profile of COVID-19 Mortality. SSRN Electronic Journal, v. 1, n.100021, sept. 2021.
FREITAS, A. R. R.; GIOVANETTI, M.; ALCANTARA, L. C. J. Variantes emergentes do SARS-CoV-2 e suas implicações na saúde coletiva. InterAmerican Journal of Medicine and Health, v. 4, 2021.
GUDBJARTSSON, D. F.; NORDDAHL, G. L.; MELSTED, P. et al. Humoral Immune Response to SARS-CoV-2 in Iceland. New England Journal of Medicine, v. 383, n. 18, p. 1724-1734, 2020.
KOCHHAR, S.; SALMON, D. A. Planning for COVID-19 vaccines safety surveillance. Vaccine, v. 38, n. 40, p. 6194-6198, 2020.
KRAUSE, P. R.; GRUBER, M. F. Emergency Use Authorization of Covid Vaccines — Safety and Efficacy Follow-up Considerations. New England Journal of Medicine, v. 383, n. 19, p. e107, 2020.
SAMANOVIC, M. I.; CORNELIUS, A. R.; GRAY-GAILLARD, S. L. et al. Robust immune responses after one dose of BNT162b2 mRNA vaccine dose in SARS-CoV-2 experienced individuals. medRxiv Preprint. 2021.
SEOW, J.; GRAHAM, C.; MERRICK, B. et al. Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans. Nature Microbiology, v. 5, n. 12, p. 1598-1607, 2020.
WIDGE, A. T.; ROUPHAEL, N. G.; JACKSON, L. A. et al. Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination. New England Journal of Medicine, v. 384, n. 1, p. 80-82, 2021.
ZHANG, Y.; ZENG, G.; PAN, H. et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. The Lancet Infectious Diseases, v. 21, n. 2, p. 181-192, 2021.
Derechos de autor 2021 Iniciação Científica Cesumar
Esta obra está bajo licencia internacional Creative Commons Reconocimiento-NoComercial 4.0. A Revista se reserva o direito de efetuar, nos originais, alterações de ordem normativa, ortográfica e gramatical, com o intuito de manter o padrão culto da língua, respeitando, porém, o estilo dos autores. As opiniões emitidas pelos autores são de sua exclusiva responsabilidade.
Juntamente com o e-mail de aceite (para casos de aprovação) será encaminhado modelo da Carta de Direitos Autorais que deverá conter o nome completo dos autores, bem como dados de documentos pessoais e assinada por todos os autores e coautores envolvidos no trabalho.